WebreSET-O prescription digital therapeutic is a 12-week (84 day) software application intended to increase retention of patients with opioid use disorder (OUD) in outpatient treatment by … WebApr 10, 2024 · Pear Therapeutics Inc. filed for bankruptcy protection under chapter 11 to buy time to sell its assets. The company was the first-to-market for prescription digital therapies, with three PDTs gaining regulatory nods from the FDA: Reset for substance use disorder, Reset-O for opioid use disorder and Somryst for insomnia. Reset-A received …

Novartis trial shows no benefits from Pear

WebFeb 25, 2024 · Pear, which went public in December through a SPAC merger, hasn't yet reported its 2024 earnings. In January, the company shared it had met its target for the year to have 14,000 prescriptions for its products. The company initially set guidance for $4 million in revenue in 2024 and hopes to increase that number to $22 million in 2024. WebreSET® is a 12-week prescription digital therapeutic for patients with substance use disorder, who are currently enrolled in outpatient treatment under the supervision of a clinician. reSET is the first FDA-authorized … gcf of 28 and 196

CMS code seen as major step toward reimbursement for digital ...

WebreSET-O is not intended to be used as stand-alone therapy for Opioid Use Disorder (OUD) and does not replace care by your provider or outpatient treatment. reSET-O is not a … WebNov 15, 2024 · Pear’s products, reSET and reSET-O, were added to MassHealth’s Non-Drug Product List, effective November 1, 2024. Pear’s PDTs were made available on major national product formularies. WebMay 16, 2024 · Pear’s product, reSET ®, for the treatment of substance use disorder, was the first PDT to receive marketing authorization from the FDA to treat disease. Pear’s second product, reSET-O ®, for the treatment of opioid use disorder, was the first PDT to receive Breakthrough Designation. gcf of 28 and 48